ASCO GU是泌尿男生殖系肿瘤领域的学术盛会,会议展示了该领域最具创新性的科学进展,并探讨泌尿男生殖系肿瘤未来的治疗方向。本届ASCO GU大会上,肾癌领域重磅研究KEYNOTE-564公布了中位随访57个月的疗效和安全性结果,医脉通编译如下,以飨...
研究标题:Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). 中文标题:辅助帕博利珠单抗对比安慰剂治疗透明细胞肾细胞癌(ccRCC)的3期KEYNOTE-564研究的总生存结果 研究背景 这项随机、多中心、双...
KEYNOTE-564 is the first phase 3 study to show improved survival with any adjuvant therapy in RCC. These results continue to support adjuvant pembrolizumab as a standard of care.Clinical trial information: NCT03142334.Toni K. ChoueiriDana-Farber Cancer Institute, Harvard Medical School, Boston, ...
MP14-05MODELING SURVIVAL OUTCOMES OF KEYNOTE-564 WITH STANDARD OF CARE CONTROL ARM TREATMENT: A SIMULATION STUDY doi:10.1097/01.JU.0001109872.73672.99.05Wolters KluwerThe Journal of UrologySpencer JamesSyed RahmanFady Ghali
In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in 20% of patients receiving KEYTRUDA; the serious adverse reactions (≥1%) were acute kidney injury, adrenal insufficiency, pneumonia, coli...
ASCO GU是泌尿男生殖系肿瘤领域的学术盛会,会议展示了该领域最具创新性的科学进展,并探讨泌尿男生殖系肿瘤未来的治疗方向。本届ASCO GU大会上,肾癌领域重磅研究KEYNOTE-564公布了中位随访57个月的疗效和安全性结果,医脉通编译如下,以飨读者。 1 研究背景...
In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in 20% of patients receiving KEYTRUDA; the serious adverse reactions (≥1%) were acute kidney injury, adrenal insufficiency, pneumonia, coli...
对于随机分配的接受至少一次研究治疗的患者进行安全性评估。研究结果 2018年10月5日到2021年8月6日，共计招募了698例患者，帕博利珠单抗组（n=350），安慰剂组（n=348）。564（81%）为雄性，134（19%）为女性。在第三次中期分析，帕博利珠单抗组286（82%）例患者，安慰剂组304（88%）例患者停止治疗，大部分...
Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. J Clin Oncol. 2021;39(suppl 15; abstr LBA5). DOI 10.1200/JCO.2021.39.15_suppl.LBA5...
值得注意的是,KEYNOTE-564研究的成功将使帕博利珠单抗成为首个对肾细胞癌辅助治疗表现出积极结果的PD-1单抗。 06 新药:一线NSCLC,阿美替尼拟纳入突破性疗法 近日,国家药品监督管理局(NMPA)官网显示,豪森药业的第三代EGFR抑制剂阿美替尼拟纳入突破性疗法,用于一线治疗EGFR突变阳性局部晚期或转移性NSCLC。